Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


Immunomodulatory Properties of Ketamine in Sepsis


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT01089361

Organisation Name: Beth Israel Deaconess Medical Center

Overal Status: Completed

Start Date: December 2009

Last Update: August 21, 2017

Lead Sponsor: Beth Israel Deaconess Medical Center

Brief Summary: The aim of the study is to assess the effect of short-term infusion of ketamine at analgesic dosage on the immune response, morbidity and mortality among patients suffering from septic shock. We hypothesize that ketamine will modulate the cytokine response to sepsis and reduce morbidity and mortality.

Conditions:
  • Sepsis


Total execution time in seconds: 0.1622371673584